## **REMARKS**

Reconsideration and reexamination is respectfully requested.

Claim 1 has been amended to correct a typographical error appearing therein.

Claims 1-3, 5, 7, 9-10, and 13-21 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over copending application 10/180,869 and US 6,492,400 and US 6,627,629. A terminal disclaimer is being submitted herewith over 10/180,869 and US 6,492,400.

The patent US 6,627,629 discloses compounds wherein the E linker is a heterocyclic moiety. There is no teaching within US 6,627,629 of the compounds of the present invention having an E linker with a carbocyclic moiety in combination with a carbonyl/sulfonyl group Therefore, the present invention is not obvious over US 6,627,629. Withdrawal of the double patenting rejection is respectfully requested.

Claims 1-3, 5, 7, 9-10, and 13-21 were rejected under Section 112, first paragraph as failing to comply with the written description requirement.

When analyzing a patent application for compliance with the written description requirement, "[t]here is a strong presumption that an adequate written description of the claimed invention is present when the application is filed," see MPEP 2163, and the office has "the initial burden of presenting by a preponderance of evidence why a person skilled in the art would not recognize in an applicant's disclosure a description of the invention". Non-compliance with the written description requirement would occur when an aspect of the claimed invention has not been described with sufficient particularity or if the claims require an essential or critical feature which is not adequately described and which is not conventional in the art, see MPEP 2163. In regard to generic claims covering chemical compounds, it is necessary to be able to define it so as to distinguish it from other materials, see MPEP 2163. The generic formula should

## REMARKS SECTION

indicate with specificity what the generic claims cover so that one skilled in the art can identify many of the species that the claims encompass, see MPEP 2163. Possession of the invention may also be shown by a clear depiction of the invention in detailed drawings or in structural chemical formulas which permit a person skilled in the art to clearly recognize that application had possession of the claimed invention, see MPEP 2163.

An applicant may show possession of an invention by disclosure of drawings or structural chemical formulas that are sufficiently detailed to show that application was in possession of the claimed invention as a whole. "In claims involving chemical materials, generic formulae usually indicate with specificity what the generic claims encompass. One skilled in the art can distinguish such a formula from others and can identify many of the species that the claims encompass. Accordingly, such a formula is normally an adequate description of the claimed genus", Regents of the University of California v. Eli Lily & Co. 119 F3d 1559, 1568.

In the present application, applicants have provided sufficient written description of the invention. The application describes the invention with great particularity, see pages 7-49. Therefore, the present invention has been described with sufficient clarity. Furthermore, the application describes detailed synthesis of compounds of the present invention. Schemes 2, 4, 5, and 6, pages 67, 70, 71, and 74, and the descriptions accompanying them describe methods for preparing pyrrolidinyls. The remaining schemes describes various methods of prepraring the other portions of the compounds of the present invention. Furthermore, Table 2, page 164, shows a variety of representative pyrrolidinyl compounds of the present invention. The application further describes the assays used in screening the compounds, see page 263-265, for CCR3 binding and human eosinophil chemotaxis. Therefore, the application provides a more than adequate written description of the present invention and enabling support for the scope of the present

## **REMARKS SECTION**

invention. Withdrawal of the Section 112 rejection is respectfully requested.

Claims 14-19 were rejected. The Office Action stated that they were reach through claims. While applicants do not agree with this rejection, solely to expedite prosecution of the application, claims 14, 17 and 18 have been cancelled without prejudice to prosecute them in a continuing application and claim 19 has been amended. Therefore, withdrawal of the Section 112 rejection against claims 14-19 is respectfully requested.

The application is now believed to be in condition for allowance and notification thereof is respectfully requested.

Respectfully submitted,

Date: October 28, 2004

Mary K. VanAtten

Attorney for Applicants Registration No. 39,408 Telephone: 609/252-4379